SL
ANIP icon

Salomon & Ludwin’s ANI Pharmaceuticals ANIP Stock Holding History

Salomon & Ludwin’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.6K Sell
248
-53
-18% -$4.25K ﹤0.01% 1126
2026
Q1 		$22.3K Buy
301
+136
+82% +$10.6K ﹤0.01% 1008
2025
Q4 		$13K Buy
165
+41
+33% +$3.55K ﹤0.01% 1259
2025
Q3 		$11.1K Buy
+124
New +$10.1K ﹤0.01% 1232

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Salomon & Ludwin's ANIP Position: Q2 2026 in Review

Salomon & Ludwin reduced its ANI Pharmaceuticals (ANIP) stake by 18% in Q2 2026, selling an estimated $4.25K and leaving 248 shares worth $20.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1126.

Salomon & Ludwin first reported a position in ANIP in Q3 2025 and has held it in 4 quarters since. The position peaked at $22.3K in Q1 2026. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Salomon & Ludwin held 248 shares of ANI Pharmaceuticals worth $20.6K as of Q2 2026.
  • Salomon & Ludwin sold 53 ANI Pharmaceuticals shares in Q2 2026, an estimated $4.25K.
  • ANI Pharmaceuticals made up ﹤0.01% of Salomon & Ludwin's portfolio in Q2 2026, its #1126 holding.
  • Salomon & Ludwin first reported a position in ANI Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Salomon & Ludwin's ANI Pharmaceuticals position peaked at $22.3K in Q1 2026.
  • 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Salomon & Ludwin's 13F filing for Q2 2026, filed 7 Aug 2026.